Charles C. Duncan was appointed Director of Vanda Pharmaceuticals Inc. As of November 6, 2026, Vanda Pharmaceuticals Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 2, 2026 to April 22, 2026, naming 1 appointment (Form 8-K, April 22, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Vanda Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Vanda Pharmaceuticals Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-02 to 2026-04-22. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Vanda Pharmaceuticals Inc. files it.
Also on the record for Vanda Pharmaceuticals Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock Portfolio Management LLC | 5.9% of the class | 5%+ stakes | Source |
| October 9, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 7% of the class | 5%+ stakes | Source |
| August 19, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 5.6% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by AQR Capital Management, LLC | 5.82% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.1% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G/A, by BlackRock Portfolio Management LLC | 4.2% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by BlackRock Portfolio Management LLC | 5.5% of the class | 5%+ stakes | Source |
| January 9, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 2.8% of the class | 5%+ stakes | Source |
| July 1, 2025 | Stake report, Schedule 13G, by Millennium Management LLC | 5.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Vanda Pharmaceuticals Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Vanda Pharmaceuticals Inc. and the records around it.
Vanda Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- BlackRock Portfolio Management LLC also filed stake reports on 118 other companies: AMERISAFE INC (Nov 2026), BlackRock ETF Trust (Nov 2026), iShares J.P. Morgan EM Local Currency Bond ETF (Nov 2026)
- Millennium Management LLC also filed stake reports on 121 other companies: StepStone Group Inc. (Nov 2026), Catalyst Acquisition Corp. (Nov 2026), RxSight, Inc. (Nov 2026)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Watch Vanda Pharmaceuticals Inc.
Get an email when Vanda Pharmaceuticals Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vanda Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Vanda Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vanda Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-22 | In | Director | 8-K, 2026-04-22 | ||
| 2026-04-02 | Reported | not named in the filing | 8-K, 2026-04-02 |
Who leads Vanda Pharmaceuticals Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Charles C. Duncan, appointed (filed 2026-04-22).
New leaders reset buying decisions — get the Full Report on Vanda Pharmaceuticals Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Vanda Pharmaceuticals Inc., with the record behind each one.
Find candidates like Director at Vanda Pharmaceuticals Inc.Every change, in the filing's words
Appointed: Charles C. Duncan, Director
(d) Election of Director On April 22, 2026, the Board of Directors (the "Board") of Vanda Pharmaceuticals Inc. (the "Company") expanded the size of the Board from six to seven members, effective immediately and appointed Charles C. Duncan, Ph.D., as a director of the Company to fill the vacancy created by the expansion.
- Dr. Duncan will serve as a Class II director with an initial term that will expire at the Company's 2026 annual meeting of stockholders.
- Pursuant to the Company's outside director compensation program, Dr. Duncan was granted an initial restricted stock unit award with a fixed grant date value equal to $390,000 as of April 22, 2026, with the number of shares of common stock underlying the award to be determined based on such value calculated in accordance with ASC 718.
- The restricted stock units will vest in four equal installments while Dr. Duncan continues to provide service as a member of the Board, with the first annual vest taking place on April 22, 2027.
- In the event of a change of control of the Company, the restricted stock units will become fully vested.
- Dr. Duncan will also receive a $50,000 annual fee, payable quarterly.
- In addition, he will be eligible to receive, upon the conclusion of each annual meeting of stockholders beginning in 2026, an additional restricted stock unit award with a fixed grant date value equal to $260,000 as of the date of the annual meeting, with the number of shares of common stock underlying the award to be determined based on such value calculated in accordance with ASC 718.
Reported
(b) Resignation of Executive Officer On March 29, 2026, Timothy Williams notified Vanda Pharmaceuticals Inc. (the "Company") of his resignation as the Company's Senior Vice President, General Counsel and Secretary, effective as of April 10, 2026, in order to pursue other endeavors.
Tools for this story
Each opens in a new tab, filled in for Vanda Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.